In the Beginning of My Life with HIV, after a coma caused by viral meningitis, there was no treatment. And therefore, no hope. I lost people, and many! Some of them just disappeared on the road, and I don't even know if they are alive or not. And as I said Martha Medeiros, a dor que dói mais é a dor e não saber!
Sobre a Vida com HIV, no que tange a mim, coisa que verdadeiramente me incomoda é a neuropatia periférica. E vejam, eu nem estou “so badly"
Treatment of HIV infection continues to improve, study shows among 77.999 people
The effectiveness of first-line antiretroviral therapy (ART) continues to improve, according to an analysis of results in 78.000 people in 181 studies, published in the Journal AIDS by Professor Andrew Carr of St Vincent's Hospital in Sydney and colleagues. More than three quarters of people who started treatment between 2011 and 2015 were still on their first regimen! And they had an undetectable viral load three years later.
The results in 2011-2015 were significantly better than those recorded in people initiating therapy between 2006 and 2010, who in turn were better at results observed in people who started treatment between 2001 and 2005 and between 1994 and 2000. In addition, there was a sustained drop in the proportion of individuals who stopped their first-line regime. In this case, there is talk of interruptions due to side effects or due to personal choices. However, the proportion of people who stopped due to virological failure was reduced by approximately 5%.
In this way, as Cazuza said: “I saw the Face of Death. And she was alive
But, however good the post-2011 results, researchers believe that it is still possible to do better. They note that even with the most up-to-date ART regimens, a fifth of people experience treatment failure (interrupt or change your treatment regimen for any reason) within three years after the initiation of HIV therapy.
The So-called TARV Involved, in 1996 in a Drug Called DDI (Imagine The Devil On Tablets)
And see it here: Videx
The study contained some indications as to which regimes were likely to be most successful: people who started treatment with tenofovir (TDF or TAF) associated with emtricitabine and integrase inhibitors were more likely to remain in first-line treatment over three years. Other findings showed that the baseline resistance test and the single daily dose were also predictors of long-term treatment success.
Five findings from the study on Treatment for HIV Infection
Five findings of special importance are highlighted by the authors:
- The initial effectiveness of ART continues to improve. However, more than 20% of patients on post-2010 integrase inhibitor-based HAART failed over 144 weeks.
- Phase 3 studies overestimate the “Real-world effectiveness”.
- There is little analysis of patient characteristics and clinical examinations collected routinely to avoid failure of ART drug routine nHIV infection and its consequences.
- The rate of interruption of ART by virological failure does not appear to have diminished in more than 20 years.
- The follow-up time of the study remains very short.
Looking Good, Antiretroviral Therapy, ART, is the guiding thread of “our lives”!
The ART treatment guidelines make recommendations for the selection of first-line therapy based on the sequential review of individual randomized trials. To obtain a more accurate impression of the effectiveness and durability of first-line ART, a strategy was needed. Thus, Carr and colleagues conducted a systematic review of the results reported in 181 studies involving 77.999 people.
Explaining, the study was from 1994 to 2017.
A similar exercise carried out in 2008 showed that Tenfovir / Emtricitabine-based therapy was more effective than treatment with abacavir / lamivudine when used with a boosted protease inhibitor or a non-nucleoside reverse transcriptase inhibitor (NNRTI).
An update in 2012 showed that treatment based on an integrase inhibitor was superior to treatment, including a potentiated protease inhibitor or NRTIs. It also showed that differences in results according to viral load were lower for the integrase inhibitors than enhanced protease inhibitors and NRTIs.
Studies on Improvement Against 0 Treatment of HIV Infection Has Not Evaluated “First Line” Treatments.
Only randomized studies and prospective cohort studies involving people starting first-line ART were included. The primary endpoint was treatment effectiveness at weeks 48, 96, and 114. Success was defined as an undetectable viral load reported based on intention to treat. Thus, changing treatment for any reason was therefore considered a failure.
Overall, patients had an average age of 37 years, 75% were men and 61% were white. At the beginning of the study, the average CD4 cell count was 262 cells / mm3. And the viral load was 63.000 copies / ml, respectively. Patients took an average of 4,8 tablets in 1,6 daily doses.
The main treatment structures were tenofovir / emtricitabine (44%), based on thymidine (28%) and abacavir / lamivudine (10%). The third main drugs were NNRTIs (50%), enhanced protease inhibitors (28%) and integrase inhibitors (12%).
Anti-HIV Treatment Has Improved Quality of Life of Diagnosed People
Results at week 48 were reported to almost all participants. The average effectiveness was 71%. It has improved significantly over time. The average was 57% in studies that started between 1994 and 2000. And it increased to 69% for people starting therapy between 2001 and 2005. And to 77% for individuals in 2006 and 2010 and to 84% in post-2010.
Efficacy at week 96 was reported in 41% of studies, with an overall rate of 64%. It increased from 52% for studies before 2000. To 61% for studies from 2001 to 2005. And so, it increased to 65% for studies from 2006 to 2010. And finally, to 80% in recruitment studies between 2011 and 2015.
Only 14% of studies reported results at week 144 and they found an overall effectiveness of 62%. Again, this has improved over time. The effectiveness rates for the four time periods were 45%, 55%, 72% and 77%, respectively.
Predictors of efficacy included the choice of the drug, with results that favor both tenofovir / entricibine and integrase inhibitors. Several dosage characteristics have also been associated with greater effectiveness: once a day at week 48; dosing without dietary restrictions at week 96; and fewer pills at weeks 96 and 144.
HIV treatment has improved a lot. Mara, My Wife, I Believe, Is Alive Only And Only Thanks to Maraviroc, an important medication in the rescue therapy in the Treatment against HIV Infection
“The type of ART used, in particular the use of an integrase inhibitor as an anchor drug and the use of a NRTI backbone once a day [nucleoside reverse transcriptase inhibitor], had a much greater impact on effectiveness than characteristics of the patient ”, comment the authors. "The number of doses per day had a stronger relationship with effectiveness than if ART was taken as a pill or more than one pill per day."
Basal resistance test (p = 0,0003) and higher cell count CD4 baseline (p = 0,0003) also predictors of greater efficacy.
The results in the post-licensing and “real world” studies were progressively worse than those seen in phase three clinical trials.
Overall, the results were about 10% better with the schemes recommended in the US Department of Health and Social Services guidelines, compared to the schemes recommended by the World Health Organization (undetectable is equal to non-transmissible?).
Side effects remain the worst part of antiretroviral therapy, the treatment against HIV infection
However, almost 30% of people with 144 weeks of follow-up prematurely stopped their initial ART regimen. The most common reasons were patient choice (13%), side effects (9%) and virological failure (5%). Most of these cessations occurred at week 48. The proportion of early treatment cessations due to patient choice or side effects was lower in studies conducted after 2010, compared to other time periods. However, the proportion of people who discontinued therapy due to virological failure remained stable at approximately 5%.
“The initial effectiveness of ART continues to improve, but more than 20% of post-2010 patients have failed in 3 years”, conclude the researchers. “The effectiveness in the real world is less than in phase 3 studies. The guidelines should list the initial ART not based on integrase inhibitors as non-preferred. Strategies are needed to improve access to pre-ART genotyping and increase the early onset of single daily ART. "
Translated by Cláudio Souza from the original HIV treatment outcomes continue to get better, says large analysis, esquito por Michael Carter, pPosted: 27 December 2018 in AIDSMAP.
My Personal Opinion
Desta forma, eu diria que sim, o tratamento melhorou desde seu “começo” em 1996? Sim, sem dúvida! E nem por iso ele seria, digamos, um passeio à praça. Se você quer minha opinião, eu diria que se eu pudesse voltar no tempo eu voltaria.
Eu voltaria e diria a mim mesmo tudo o que eu sei. “O que agora eu sei”. E diria a mim mesmo para “tomar outra rota”. Isso certamente geraria um paradoxo e você não estaria aqui, “me lendo”.
Isso não seria possível. Mas se fosse…. Bem, quando se trata de paradoxos temporais e atemporais, o melhor é nem começar a pensar.
A grande verdade é que, neste momento, em vinte e oito de dezembro de dois mil e dezoito, por volta das 13:00, o que eu posso é afirmar:
The Stupid VontAIDS thing
E que é estúpida a colocação que reza ser melhor die of AIDS than of Vont'AIDS
Take care. Ever
[contact-form] [contact-field label = 'Name' type = 'name' required = '1' /] [contact-field label = 'Email' type = 'email' required = '1' /] [ contact-field label = 'Site' type = 'url' /] [contact-field label = 'Comment' type = 'textarea' required = '1' /] [/ contact-form]
Carr A et al. Success and failure of initial antiretroviral therapy in adults: an updated systematic review of 77.999 patients from 1994 to 2017. AIDS, online edition. DOI: 10.1097 / QAD.0000000000002077 (2018).